Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

Reproductive Biology and Endocrinology

Juan A Garcia-Velasco²  Antonio Pellicer³  Carlos Iglesias¹  Alfonso Bermejo¹  Azucena Zapata¹  Erik E Hauzman¹ 

[1] IVI Madrid, Avda del Talgo, 68-70, 28023 Madrid, Spain;Rey Juan Carlos University, Avda del Talgo 68-70, 28023 Madrid, Spain;Universidad de Valencia, Avda de Blasco Ibáñez, 13, 46010 Valencia, Spain

关键词: Estrogen pretreatment;    Oral contraceptives;    Cycle scheduling;    GnRH antagonist;    IVF;   

Others  :  809934
DOI  :  10.1186/1477-7827-11-96

 received in 2013-08-03, accepted in 2013-09-24,  发布年份 2013

【 摘 要 】

Background

Both oral contraceptive pills (OCPs) and estradiol (E₂) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E₂ valerate.

Methods

Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts) undergoing IVF with the GnRH antagonist protocol were randomized to either the OCP or E₂ pretreatment arms, with no restrictions such as blocking or stratification. Authors involved in data collection and analysis were blinded to group assignment. Fifty patients received OCP (30 μg ethinyl E₂/150 μg levonorgestrel) for 12–16 days from day 1 or 2, and stimulation was started 5 days after stopping OCP. Similarly, 50 patients received 4 mg/day oral E₂ valerate from day 20 for 5–12 days, until the day before starting stimulation.

Results

Pretreatment with OCP (mean±SD, 14.5±1.7 days) was significantly longer than with E₂ (7.8±1.9 days). Stimulation and embryological characteristics were similar. Ongoing pregnancy rates (46.0% vs. 44.0%; risk difference, –2.0% [95% CI –21.2% to 17.3%]), as well as implantation (43.5% vs. 47.4%), clinical pregnancy (50.0% vs. 48.0%), clinical miscarriage (7.1% vs. 7.7%), and live birth (42.0% vs. 40.0%) rates were comparable between groups.

Conclusions

This is the first study to directly compare these two methods of cycle scheduling in GnRH antagonist cycles. Our results fail to show statistically significant differences in ongoing pregnancy rates between pretreatment with OCP and E₂ for IVF with the GnRH antagonist protocol. Although the study is limited by its sample size, our results may contribute to a future meta-analysis. An interesting future direction would be to extend our study to women with decreased ovarian reserve, as these are the patients in whom an increase in oocyte yield—due to the hypothetical beneficial effect of steroid pretreatment on follicular synchronization—could more easily be demonstrated.

Trial registration

ClinicalTrials.gov http://NCT01501448 webcite.

【 授权许可】

   
2013 Hauzman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, Ledger W, Tomás C, Fauser BC: Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009, 24:764-774.
• [2]Al-Inany HG, Youssef MAFM, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011., 5CD001750
• [3]Mortimer D, Mortimer ST: Quality and risk management in the IVF laboratory. Cambridge: Cambridge University Press; 2005.
• [4]González RM, Canales E, García R, Martín C, Roldán M, Fernández M, Prados N: Recuperación real de la temperatura y porcentaje de CO2 en los incubadores de fecundación in vitro. In Proceedings of the XXIth national congress of AETEL. Madrid: AETEL; 2008.
• [5]Janssens R, Souffreau R, Haentjens P, Van de Velde H, Verheyen G: Clinical outcome after culturing human preimplantation embryos in incubators with individual chambers compared to standard incubators; randomised trial [abstract]. Hum Reprod 2011, 26:i40-i41.
• [6]Frydman R, Forman R, Rainhorn JD, Belaisch-Allart J, Hazout A, Testart J: A new approach to follicular stimulation for in vitro fertilization: programmed oocyte retrieval. Fertil Steril 1986, 46:657-662.
• [7]Wardle PG, Foster PA, Mitchell JD, McLaughlin EA, Williams JAC, Corrigan E, Ray BD, McDermott A, Hull MG: Norethisterone treatment to control timing of IVF cycle. Hum Reprod 1986, 1:455-457.
• [8]Zorn JR, Boyer P, Guichard A: Never on a Sunday: programming for IVF-ET and GIFT. Lancet 1987, 1(8529):385-386.
• [9]Gerli S, Remohí J, Partrizio P, Borrero C, Balmaceda JP, Silber SJ, Asch RH: Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles. Hum Reprod 1989, 4:746-748.
• [10]de Ziegler D, Jääskelaïnen AS, Brioschi PA, Fanchin R, Bulletti C: Synchronisation of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod 1998, 13:561-564.
• [11]Rombauts L, Healy D, Norman RJ: Comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 2006, 13:235-245.
• [12]Kolibianakis EM, Papanikolau EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P: Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 2006, 21:352-357.
• [13]Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B: Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010, 94:2382-2384.
• [14]Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM: Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008, 90:1055-1063.
• [15]Garcia-Velasco JA, Bermejo A, Ruiz F, Martínez Salazar J, Requena A, Pellicer A: Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril 2011, 96:590-593.
• [16]Le Nestour E, Marraoui J, Lahlou N, Roger M, de Ziegler D, Bouchard P: Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal–follicular transition. J Clin Endocrinol Metab 1993, 77:439-442.
• [17]Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R: Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003, 18:2698-2703.
• [18]Blockeel C, Engels S, De Vos M, Haentjens P, Polyzos NP, Stoop D, Camus M, Devroey P: Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reprod Biomed Online 2012, 24:272-280.
• [19]Cédrin-Durnerin I, Guivarc’h-Levêque A, Hugues JN: Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril 2012, 97:1359-1364.
• [20]Ye H, Huang GN, Zeng PH, Pei L: IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long agonist protocol: a prospective and randomized study. J Assist Reprod Genet 2009, 26:105-111.
• [21]Fanchin R, Schönauer LM, Cunha-Filho JS, Méndez Lozano DH, Frydman R: Coordination of antral follicle growth: basis for innovative concepts of controlled ovarian hyperstimulation. Semin Reprod Med 2005, 23:354-362.
• [22]Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47.
• [23]Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN: Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod 2007, 22:109-116.
• [24]Guivarc’h-Levêque A, Homer L, Arvis P, Broux PL, Moy L, Priou G, Vialard J, Colleu D, Dewailly D: Programming in vitro fertilization retrievals during working days after a gonadotropin-releasing hormone antagonist protocol with estrogen pretreatment: does the length of exposure to estradiol impact on controlled ovarian hyperstimulation outcomes? Fertil Steril 2011, 96:872-876.
• [25]van Heusden AM, Fauser BC: Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002, 8:345-358.
• [26]Phillips A, Hahn DW, Klimek S, McGuire JL: A comparison of the potencies and activities of progestogens used in contraceptives. Contracept 1987, 36:181-192.
• [27]Barad DH, Kim A, Kubba H, Weghofer A, Gleicher N: Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? - a pilot study. Reprod Biol Endocrinol 2013, 11:28-33. BioMed Central Full Text
• [28]Barmat LI, Chantilis SJ, Hurst BS, Dickey RP: A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 2005, 83:321-330.
• [29]Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P: Prolongation of follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle- stimulating hormone and gonadotrophin-releasing hormone antagonists. Fertil Steril 2004, 82:102-107.
• [30]Tremellen KP, Lane M: Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod 2010, 25:1219-1224.
• [31]Orvieto R, Kruchkovich J, Rabinson J, Zohav E, Anteby EY, Meltcer S: Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil Steril 2008, 90:228-230.
• [32]Orvieto R: The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the "detrimental effect" of the oral contraceptive. Fertil Steril 2012, 98:e17-18.